Carregant...
Dabrafenib and trametinib in BRAFV600E mutated glioma
BRAFV600E mutations have been identified in a number of glioma subtypes, most frequently in pleomorphic xanthoastrocytoma, ganglioglioma, pilocytic astrocytoma, and epithelioid glioblastoma. Although the development of BRAF inhibitors has dramatically improved the clinical outcome for patients with...
Guardat en:
| Publicat a: | CNS Oncol |
|---|---|
| Autors principals: | , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Future Medicine Ltd
2017
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6004887/ https://ncbi.nlm.nih.gov/pubmed/28984141 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2217/cns-2017-0006 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|